Royal Bank of Canada
HCWB icon

Royal Bank of Canada’s HCW Biologics HCWB Stock Holding History

Royal Bank of Canada’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2
Closed – – 7082
2024
Q2 		$0 Buy
2
+1
+100% +$295 ﹤0.01% 7251
2024
Q1 		$0 Hold
1
– – ﹤0.01% 7236
2023
Q4 		$0 Buy
+1
New +$341 ﹤0.01% 7310
2023
Q3 		– Sell
-1
Closed – – 7279
2023
Q2 		$0 Buy
+1
New +$398 ﹤0.01% 7406
2022
Q4 		– Sell
-1
Closed – – 7420
2022
Q3 		$0 Buy
+1
New +$573 ﹤0.01% 7603

Other funds holding HCWB

APP
Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PIM
Pullen Investment Management Bradenton, Florida $216M AUM 32.94% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AWM
AE Wealth Management Topeka, Kansas $21.5B AUM 26.98% 1-Year Est. Return

Royal Bank of Canada's HCWB Position: Q3 2024 in Review

Royal Bank of Canada sold out of HCW Biologics (HCWB) in Q3 2024, closing a stake of 2 shares.

Royal Bank of Canada first reported a position in HCWB in Q3 2022 and held it in 5 quarters. The position peaked at $0 in Q2 2024. 16 funds tracked by Wall St. Rank hold HCWB as of Q3 2024.

  • Royal Bank of Canada reported no remaining HCW Biologics position as of Q3 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 2 HCW Biologics shares in Q3 2024.
  • Royal Bank of Canada first reported a position in HCW Biologics in Q3 2022 and held it in 5 quarters.
  • Royal Bank of Canada's HCW Biologics position peaked at $0 in Q2 2024.
  • 16 funds tracked by Wall St. Rank held HCW Biologics as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.